A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance

O’Sullivan, Eoin; Ashley, David T.; Davenport, Colin; Penugonda, Lakshmi; Kelleher, Grainne; Devlin, Niamh; Crowley, Rachel; O’Shea, Paula; Agha, Amar; Thompson, Chris; O'Gorman, Donal J.; Smith, Diarmuid

doi:10.1016/j.metabol.2012.06.005

Cited by 15 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, one study involving a group of newly diagnosed individuals with diabetes and normal controls found that OPG and HOMA-IR are positively correlated (29). Our results, however, in a group of persons with type 2 diabetes with a longer duration of diabetes were in contrast to these findings but in agreement with another study of individuals with abnormal glucose tolerance in which no association between HOMA-IR and OPG was found (30). It is also possible that poor glycemic control may affect OPG levels.…”

Section: Discussionsupporting

confidence: 90%

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

Objective Coronary artery calcification (CAC) is a prominent feature of atherosclerosis and is associated with cardiovascular events. In vitro studies have suggested that osteoprotegerin (OPG) and osteocalcin (OC) exert anticalcification potential in the vessel wall. The objective of this study was to investigate the association of CAC and serum bone biomarkers in persons with type 2 diabetes. Methods We examined 50 individuals with type 2 diabetes. CAC imaging was performed by multidetector computed tomography. CAC scores ≥10, expressed in Agatston units, were considered abnormal. OC, undercarboxylated OC (ucOC), and OPG levels were determined by enzyme-linked immunosorbent assay. Results Abnormal CAC scores were found for 64% of the study cohort. OPG levels were significantly elevated (5.5 ± 2.0 pmol/L vs. 4.2 ± 1.7 pmol/L; P = .026) for those with abnormal CAC scores. No univariate differences were found for OC or ucOC. Logistic regression analyses revealed that an increase in serum OPG level was significantly associated with an increase in CAC score (odds ratio, 3.324; 95% confidence interval, 1.321 to 8.359; P = .011). Longer duration of diabetes was a significant covariate (P = .026), whereas nonsignificant covariates in the final model were age, gender, systolic blood pressure, body mass index, insulin resistance determined by the homeostasis model assessment for insulin resistance, leptin, adiponectin, and glycemic control. The Nagelkerke R2 for the model was 0.66. Neither OC nor ucOC were significantly associated with elevated CAC scores. Conclusion Our results suggest that OPG is a more useful serum biomarker than OC or ucOC for identifying those at increased risk of arterial calcification in type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 90%

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recently, O'Sullivan et al in their cohort of 115 men with abnormal glucose tolerance test reported that OPG is not correlated with HOMA-index and the higher serum concentrations of OPG in T2DM subjects could be caused by other unknown factors [42]. Interestingly, some studies have demonstrated serum OPG is also elevated in patients affected by T1DM, suggesting that hyperinsulinemia and IR are unlikely to play a key role in the OPG induction [43,44].…”

Section: Discussionmentioning

confidence: 98%

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Esteghamati

Afarideh

Feyzi

et al. 2015

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

“…Yaturu et al showed that OPG levels significantly correlated with insulin and insulin resistance [ 41 ]. Besides, O'Sullivan et al [ 62 ] tested after a 75 g oral glucose tolerance test and OPG was higher in individuals with abnormal glucose tolerance but OPG did not correlate with HOMA-IR. Moreover, Hofsø et al [ 63 ] demonstrated that oral glucose suppressed OPG levels, independently of obesity and glucose tolerance status indicating that glucose may be involved in the acute regulation of these proteins.…”

Section: Osteoprotegerin In Clinical Studiesmentioning

confidence: 99%

Osteoprotegerin in Cardiometabolic Disorders

Ciriza

Lawrie

Varo

2015

International Journal of Endocrinology

View full text Add to dashboard Cite

Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

show abstract

A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance

Cited by 15 publications

References 20 publications

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes

Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Osteoprotegerin in Cardiometabolic Disorders

Contact Info

Product

Resources

About